window.location = \"http://www.speculatingstocks.com/pulse/stock/$userSymbol\""; exit; } ?>
"; } ?>
     
 

June 17, 2007

SpeculatingStocks.com Stock Pick: Novacea, Inc. (NOVC)

Stock Price: $10.27


Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing therapies for the treatment of cancer. The company's lead product candidate is Asentar, a promising prostate cancer drug currently in Phase III clinical trials for the treatment of glioblastoma multiforme.

NOVC recently ran to over $17.00 from the $7.00 level after the company announced a lucrative partnership deal with pharmaceutical giant, Schering-Plough. The deal is potentially worth over $500 million to jointly develop Novacea's Asentar.

We expect further positive news out of NOVC. Considering the Schering-Plough deal, we believe NOVC is significantly undervalued down at a market cap of only around $238 million.

NOVC has a strong balance sheet with over $56 million in cash and short-term investments on the balance sheet as of March 31, 2007.

NOVC's chart has corrected from its high and is now stabilizing for another possible run higher.